Cancer Cachexia Market

The global Cancer Cachexia Market is valued at USD 2.65 Billion in 2024 and is projected to reach a value of USD 4.11 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.3% between 2025 and 2035.

Key Highlights:

• The North American region led the Cancer Cachexia market in 2024, with 47.5% of the total market share,
• The Asia Pacific region is anticipated to register the fastest growth rate during the forecast period,
• In 2024, the Progestogens segment took the lead in the Cancer Cachexia market, contributing 57.4% of considerable revenue share,
• Based on the segmentation of the Distributional Channel, the Hospital Stores segment significantly contributed to the Cancer Cachexia market’s expansion in 2024, over 53.2% of the market share,
• Advances in technology, such as biomarkers for early detection and monitoring of cachexia, are improving diagnosis and treatment outcomes. Wearable devices and telemedicine also play a role in patient management and care.

Regional Overview:

The North America Cancer Cachexia market exhibited significant dominance in 2024, with 47.5% of revenue share. The North American region is poised for significant growth within the Cancer Cachexia Market, driven by factors such as the increasing incidence of cancer patients and subsequent cases of Cancer Cachexia. This growth is reinforced by the presence of numerous drug manufacturers and key industry players, alongside advancements in the care paradigm for cancer patients, bolstering the regions market dominance. Additionally, the rising elderly population and escalating healthcare expenditure, and advanced healthcare infrastructure further contribute to stimulating market growth in this region.

U.S. and Canada Cancer Cachexia Market Overview

Within North America, the United States and Canada collectively exhibit remarkable dominance in the Cancer Cachexia Market. In 2019 alone, the U.S. accounted for approximately 1.8 million cancer patients and over 606,000 deaths, with projections indicating continued growth. This dominance is fueled by factors including the high prevalence of Cancer Cachexia, increasing awareness of cancer-supportive care, and the availability of robust reimbursement models. Additionally, the increasing number of pipeline drugs in Phase III clinical trials is poised to amplify market share in the coming years, further solidifying the sectors supremacy. The enhanced affordability among patients bolsters sector dominance, with the proliferation of awareness programs related to cancer care further driving market growth in the region.

Therapeutics Overview

• In 2024, the Progestogens segment dominated the Global Cancer Cachexia market with 57.4% of revenue share. Based on Therapeutics, the Global Cancer Cachexia market is segmented into Progestogens, Corticosteroids, Combination Therapies, and Others.
• Progestogens emerge as the cornerstone in combating Cancer Cachexia globally. The remarkable dominance of progestogens stems from their proven efficacy and widespread adoption across diverse patient demographics and cancer types. Healthcare professionals and patients trust progestogens due to their ability to manage cachexia symptoms effectively. Progestogens' versatility in treating various cancer types and stages further cements their position as the preferred choice for cachexia management.
• The Progestogens segment maintains its stronghold through relentless research and innovation. Continuous exploration of new formulations, delivery methods, and combination therapies underscores stakeholders' commitment to enhancing the effectiveness & accessibility of progestogen-based treatments. This dedication ensures that progestogens remain at the forefront of addressing the complex challenges posed by Cancer Cachexia, reaffirming their enduring dominance in the market.

Key Trends

1. The increasing incidence of various types of cancer globally is driving the demand for effective Cancer Cachexia treatments. This rise is fueling R&D in the field, leading to new and innovative therapies.
2. Significant progress in drug discovery & development, including the advent of targeted therapies and biologics, is a key trend. These advancements aim to improve the management of Cancer Cachexia and enhance patient quality of life.
3. Combination therapies that target various pathways related to Cancer Cachexia are gaining popularity. These treatment approaches usually combine nutritional support, pharmaceutical treatments, and exercise regimens.
4. Governments & private organizations are increasingly investing in Cancer Cachexia research. This funding supports clinical trials, the development of novel treatments, and the exploration of underlying mechanisms of the condition.
5. Increased awareness & education about Cancer Cachexia among healthcare professionals and patients are leading to earlier diagnosis and better management of the condition. Educational campaigns and support groups are contributing to this trend.

Innovative Funding and Collaborative Research

• Innovative Funding for Cancer Cachexia Research: Actimed Therapeutics Ltd, a UK-based pharmaceutical company specializing in Cancer Cachexia treatment, secured over £5 million in a Series A financing round in June 2023. The round was oversubscribed, indicating strong investor interest. Noteworthy backers included Mankind Pharma, a prominent India-based pharmaceutical company. This funding will propel the development of Actimeds pipeline, particularly advancing S-pindolol benzoate through a Phase 2b/3 program named the "IMPACT" program. The focus lies on addressing Cancer Cachexia in non-small cell lung and colorectal cancer, reflecting a commitment to innovative approaches to tackling this challenging condition.
• Collaborative Research Initiative for Global Cancer Cachexia: Rutgers Cancer Institute, under the leadership of Deputy Director & Chief Scientific Officer Eileen White, PhD, spearheads a groundbreaking research endeavor to combat Cancer Cachexia. This initiative, supported by a $25 million Cancer Grand Challenges grant, exemplifies a collaborative approach to understanding and addressing the complexities of Cancer Cachexia. The CANCAN (Cancer Cachexia Action Network) team, comprising experts from Rutgers Cancer Institute, Weill Cornell Medicine, & Cold Spring Harbor Laboratory, aims to unravel the mechanisms underlying this debilitating syndrome. By uniting specialists in cancer, metabolism, neuroendocrine function, & immunology across multiple institutions in the U.S. and the UK, the team endeavors to establish the worlds first virtual institute dedicated to solving Cancer Cachexia. This initiative holds promise for pioneering interventions that could significantly enhance treatment outcomes, quality of life, and ultimately, survival rates for individuals affected by Cancer Cachexia.

Premium Insights

According to the U.S. National Institutes of Health (NIH), cachexia affects up to 87% of patients with pancreatic and gastric cancers, 61% of those with colon, lung, and prostate cancers, and non-Hodgkin lymphoma, and 40% of patients with breast cancer, sarcoma, leukemia, and Hodgkin lymphoma. Cachexia is responsible for 20% of all cancer-related deaths and indicates a poor prognosis. This condition develops as a secondary disease in cancer patients, leading to progressive dysfunction marked by a systemic inflammatory response, negative protein-energy balance, and involuntary loss of lean body mass, sometimes accompanied by a loss of adipose tissue. Clinically, cachexia results in significant weight loss in adults or inhibited growth in children, along with changes in body composition and biological system imbalances. The most noticeable symptom is decreased skeletal muscle mass, often accompanied by the depletion of fat and heart muscle. Over time, the understanding and diagnosis of cachexia in cancer patients have evolved from being seen merely as "unintentional weight loss" to being recognized as "Cancer Cachexia." Ongoing clinical trials and nutritional interventions for new treatments are continuously being developed and promoted. Multimodal interventions, which include drugs, nutritional supplements, and adequate exercise, are feasible and safe for patients with Cancer Cachexia.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Global Impact of Cancer on Cachexia Prevalence

The surge in Cancer cases globally is driving up the prevalence of cachexia, spurring demand for effective treatments. WHO estimates indicate a significant rise in new cancer cases, with cachexia affecting a notable percentage of patients, particularly those with cancer. With the absence of approved drugs for cachexia treatment, both doctors and cancer patients are exploring alternative therapies, often resorting to monotherapy with corticosteroids and progestogens. However, the industry is witnessing growth by developing combined medical and nutritional approaches, offering safer and more effective treatment options. Companies are investing in research and development to expand the availability of drugs for Cancer Cachexia, facilitating easier patient adoption and contributing to market growth.

Elevating Understanding and Demand for Cancer Cachexia Treatment

The growing recognition of Cancer Cachexia and its importance and the increasing need for treatments highlight the necessity for enhanced research and development endeavors to create a strong product lineup. This expansion is also backed by encouraging findings from randomized trials of novel drugs and the growing use of combined chemotherapy in adjuvant settings to improve survival rates. Recognition of the benefits of combination chemotherapy in improving survival rates is expected to propel further the rapid growth of Cancer Cachexia treatment. Researchers are exploring various pharmacological treatments & chemical compounds, with NSAIDs showing promising results in this regard.

Competitive Landscape

• The existing market remains relatively untapped due to the limited number of companies involved and the absence of approved treatments, particularly for addressing Cancer Cachexia. This creates substantial growth potential for other participants to seize a significant portion of the market by introducing novel products.
• In February 2022, Veru Inc., an oncology biopharmaceutical company, announced a clinical trial collaboration with Eli Lilly to evaluate enobosarm in combination with Verzenio® (abemaciclib) in a Phase 3 trial for AR+ER+HER2- metastatic breast cancer, set to begin in Q1 2022. The ENABLAR-2 trial will assess this combinations efficacy and safety, potentially offering a second-line therapy option. Enobosarm, an oral selective androgen receptor agonist, has shown promise in muscle building and fat reduction, addressing key Cancer Cachexia symptoms. Preclinical studies demonstrated significant anti-tumor activity when combined with a CDK4/6 inhibitor. Veru will conduct the trial with Lilly supplying Verzenio®, involving 186 patients across 35 U.S. sites. Enobosarms favorable side effect profile and extensive clinical experience, including 25 studies with over 1,450 subjects, highlight its potential in Cancer Cachexia management.

Recent Market Developments

Bristol Myers Squibbs Data Showcase at 2024 ASCO and EHA Congress

• In May 2024, Bristol Myers Squibb Company (U.S.) revealed that it will present data from its oncology and hematology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. The data, derived from over 130 company-sponsored studies, investigator-sponsored studies, and collaborations, will cover findings across nearly 25 types of cancer and serious blood disorders.

ARTHEx Biotechs Breakthrough Drug Delivery Platform

• In June 2022, ARTHEx Biotech has developed a groundbreaking drug delivery platform to target challenging diseases through investigational oligonucleotides that inhibit microRNAs (miRNAs). Focusing on diseases like Myotonic Dystrophy Type 1 (DM1), which lacks effective treatments, the companys flagship drug, ATX-01, offers hope by addressing the root cause of DM1. Led by CEO and Founder Dr. Beatriz Llamusí, ARTHEx Biotech is committed to addressing unmet medical needs, including myotonic dystrophy, Cancer Cachexia, and osteoarthritis. Their proprietary platform promises precise drug delivery to affected tissues, maximizing effectiveness and safety. With ongoing developments targeting Cancer Cachexia and plans to expand their pipeline, ARTHEx Biotech seeks Series A funding to validate its approach in humans and advance the platforms capabilities.

The global Cancer Cachexia market can be categorized as Therapeutics, Mechanism of Action, Distributional Channel, and Region.